Liquidia’s (LQDA) Buy Rating Reaffirmed at HC Wainwright

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $29.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 81.36% from the stock’s previous close.

A number of other analysts have also recently commented on LQDA. Scotiabank reiterated an “outperform” rating on shares of Liquidia in a research report on Monday, May 5th. Raymond James boosted their price target on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a research report on Friday, May 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $27.13.

Liquidia Stock Performance

LQDA opened at $15.99 on Monday. The business’s 50-day simple moving average is $14.25 and its 200-day simple moving average is $13.21. Liquidia has a one year low of $8.26 and a one year high of $16.81. The stock has a market capitalization of $1.37 billion, a P/E ratio of -9.81 and a beta of 0.24.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. On average, equities research analysts forecast that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of Liquidia stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now owns 1,006,420 shares of the company’s stock, valued at approximately $13,657,119.40. The trade was a 1.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Russell Schundler sold 5,964 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the sale, the general counsel now directly owns 570,301 shares in the company, valued at $7,738,984.57. This trade represents a 1.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,138 shares of company stock worth $450,233 in the last quarter. Company insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of the company. Kovitz Investment Group Partners LLC purchased a new position in Liquidia in the 1st quarter valued at approximately $384,000. Nuveen LLC purchased a new position in Liquidia in the 1st quarter valued at approximately $2,642,000. Aigen Investment Management LP purchased a new stake in shares of Liquidia in the 1st quarter worth about $151,000. CenterBook Partners LP purchased a new stake in shares of Liquidia in the 1st quarter worth about $1,786,000. Finally, Hurley Capital LLC purchased a new stake in shares of Liquidia in the 1st quarter worth about $32,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).